|
KMID : 0614620070500060350
|
|
Korean Journal of Gastroenterology
2007 Volume.50 No. 6 p.350 ~ p.355
|
|
|
COX-2 Inhibitors in Inflammatory Bowel Disease: Friends or Foes?
|
|
Park Young-Sook
|
|
|
Abstract
|
|
|
|
The cyclooxygenase (COX) is a key enzyme in the coversion of arachidonic acid to prostaglandins. COX-1 is constitutively expressed and is a critical housekeeping gene, whereas COX-2 is rapidly upregulated by growth factors and cytokines and thus responsible for inflammation. COX-2 is frequently overexpressed in colonic adenoma and carcinoma. Specific inhibitors of COX-2 have been shown to induce apoptosis in tumor cells and to inhibit tumor growth in animal models and in humans. Long-standing IBD patients have increased risk of developing colorectal cancer compared to general population. IBD-associated colorectal carcinogenesis is probably promoted by chronic inflammation and closely related to COX-2. In a recent study, powerful chemopreventive ability of selective COX-2 inhibitor was observed in colitis-related colon carcinogenesis in mouse model. But it was reported that even selective COX inhibitors aggravated the DSS-induced colonic inflammation. It is assumed that endogenous PGs are involved in the mucosal defense against DSS-induced colonic ulcerations which are produced by COX-1 at early phase and by COX-2 at late phase. Long-term use of COX-2 inhibitors for the chemoprevention of colitic cancer is needed to define their mechanism of action, that reduce side effects and have specific tumor target. (Korean J Gastroenterol 2007;50:350-355)
|
|
|
KEYWORD
|
|
|
Cyclooxygenase 2 inhibitors, Inflammmatory bowel disease
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|